Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

摘要: Metastatic colorectal cancer (mCRC) that harbours a BRAF V600E mutation (BRAF MT) is associated with poorer outcomes. However, whether this predictive of treatment benefit from anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) uncertain. We conducted systematic review and meta-analysis randomised controlled trials (RCTs) published up to July 2014 evaluated the effect MT on anti-EGFR mAbs for mCRC. Seven RCTs met inclusion criteria assessment overall survival (OS), whereas eight progression-free (PFS). For RAS WT/BRAF tumours, hazard ratio OS was 0.97 (95% CI; 0.67–1.41), 0.81 0.70–0.95) WT tumours. test interaction (P=0.43) not statistically significant, highlighting observed differences in according status may be due chance alone. Regarding PFS mAbs, 0.86 0.61–1.21) tumours as compared 0.62 0.50–0.77) (test interaction, P=0.07). This demonstrates there insufficient evidence definitively state individuals attain different mCRC individuals. As such, are data justify exclusion mAb therapy patients